Literature DB >> 20440281

Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development.

Xavier Sagaert1, Eric Van Cutsem, Gert De Hertogh, Karel Geboes, Thomas Tousseyn.   

Abstract

Mucosa-associated lymphoid tissue (MALT) lymphoma, or extranodal marginal zone lymphoma of MALT, is an indolent B-cell non-Hodgkin lymphoma arising in lymphoid infiltrates that are induced by chronic inflammation in extranodal sites. The stomach is the most commonly affected organ, in which MALT lymphoma pathogenesis is clearly associated with Helicobacter pylori gastroduodenitis. Gastric MALT lymphoma has attracted attention because of the involvement of genetic aberrations in the nuclear factor kappaB (NFkappaB) pathway, one of the most investigated pathways in the fields of immunology and oncology. This Review presents gastric MALT lymphoma as an outstanding example of the close pathogenetic link between chronic inflammation and tumor development, and describes how this information can be integrated into daily clinical practice. Gastric MALT lymphoma is considered one of the best models of how genetic events lead to oncogenesis, determine tumor biology, dictate clinical behavior and represent viable therapeutic targets. Moreover, in view of the association of gastric MALT lymphoma with dysregulation of the NFkappaB pathway, this signaling pathway will be discussed in depth in both normal and pathological conditions, highlighting strategies to identify new therapeutic targets in this lymphoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440281     DOI: 10.1038/nrgastro.2010.58

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  114 in total

1.  Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation.

Authors:  O Gaide; F Martinon; O Micheau; D Bonnet; M Thome; J Tschopp
Journal:  FEBS Lett       Date:  2001-05-11       Impact factor: 4.124

2.  TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Sivasundaram Karnan; Yoshifusa Aizawa; Won Seog Kim; Yoon-Duk Kim; Young-Hyeh Ko; Masao Seto
Journal:  Genes Chromosomes Cancer       Date:  2008-01       Impact factor: 5.006

3.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

Authors:  A H Banham; N Beasley; E Campo; P L Fernandez; C Fidler; K Gatter; M Jones; D Y Mason; J E Prime; P Trougouboff; K Wood; J L Cordell
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

4.  Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92.

Authors:  P Koch; F del Valle; W E Berdel; N A Willich; B Reers; W Hiddemann; B Grothaus-Pinke; G Reinartz; J Brockmann; A Temmesfeld; R Schmitz; C Rübe; A Probst; G Jaenke; H Bodenstein; A Junker; C Pott; J Schultze; A Heinecke; R Parwaresch; M Tiemann
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

5.  Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection.

Authors:  A Morgner; N Lehn; L P Andersen; C Thiede; M Bennedsen; K Trebesius; B Neubauer; A Neubauer; M Stolte; E Bayerdörffer
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

6.  MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.

Authors:  Hongtao Ye; Liping Gong; Hongxiang Liu; Rifat A Hamoudi; Sima Shirali; Liza Ho; Andreas Chott; Berthold Streubel; Reiner Siebert; Stefan Gesk; Jose I Martin-Subero; John A Radford; Sankar Banerjee; Andrew G Nicholson; Renzo Ranaldi; Ellen D Remstein; Zifen Gao; Jie Zheng; Peter G Isaacson; Ahmet Dogan; Ming-Qing Du
Journal:  J Pathol       Date:  2005-02       Impact factor: 7.996

7.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

8.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Translocation t(11;18)(q21;q21) in gastric B-cell lymphomas.

Authors:  Sonia Toracchio; Hiroyoshi Ota; Daphne de Jong; Andrew Wotherspoon; Massimo Rugge; David Y Graham; Amir Samani; Hala M T El-Zimaity
Journal:  Cancer Sci       Date:  2009-03-23       Impact factor: 6.716

10.  Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series.

Authors:  W Fischbach; M E Goebeler; A Ruskone-Fourmestraux; T Wündisch; A Neubauer; M Raderer; A Savio
Journal:  Gut       Date:  2007-07-16       Impact factor: 23.059

View more
  46 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

2.  Extranodal Marginal Zone B Cell (MALT) Lymphoma of the Esophagus.

Authors:  James H Tabibian; Amir Kalani; Anna M Moran; Kashyap Panganamamula
Journal:  J Gastrointest Cancer       Date:  2019-12

3.  Gastric mucosa-associated lymphoid tissue lymphomas and Helicobacter pylori infection: a Colombian perspective.

Authors:  Sally Yepes; Maria Mercedes Torres; Carlos Saavedra; Rafael Andrade
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

4.  Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population.

Authors:  Jenika M Howell; Iwona Auer-Grzesiak; Jianguo Zhang; Christopher N Andrews; Douglas Stewart; Stefan J Urbanski
Journal:  Can J Gastroenterol       Date:  2012-07       Impact factor: 3.522

Review 5.  Adjuvants and lymphoma risk as part of the ASIA spectrum.

Authors:  Dana Butnaru; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 6.  API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.

Authors:  Shaun Rosebeck; Megan S Lim; Kojo S J Elenitoba-Johnson; Linda M McAllister-Lucas; Peter C Lucas
Journal:  World J Biol Chem       Date:  2016-02-26

7.  Stimulation of dendritic cells with Helicobacter pylori vacuolating cytotoxin negatively regulates their maturation via the restoration of E2F1.

Authors:  J M Kim; J S Kim; D Y Yoo; S H Ko; N Kim; H Kim; Y-J Kim
Journal:  Clin Exp Immunol       Date:  2011-10       Impact factor: 4.330

8.  Gastrointestinal B-cell lymphomas: From understanding B-cell physiology to classification and molecular pathology.

Authors:  Xavier Sagaert; Thomas Tousseyn; Rhonda K Yantiss
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

Review 9.  Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.

Authors:  Marta-Isabel Pereira; José Augusto Medeiros
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 10.  Role of Helicobacter pylori virulence factor cytotoxin-associated gene A in gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Hong-Ping Wang; Yong-Liang Zhu; Wei Shao
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.